2-ethyl-8-methyl-2,8-diaza-spiro[4.5]decane | 64097-84-3

• 英文名称: 2-ethyl-8-methyl-2,8-diaza-spiro[4.5]decane
• 英文别名: 2-Ethyl-8-methyl-2,8-diazaspiro[4.5]decane
• CAS: 64097-84-3
• 化学式: C₁₁H₂₂N₂
• 分子量: 182.309
• InChiKey: QMUNEBPTTOJKLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-乙基-8-甲基-2,8-二氮杂螺[4.5]-1,3-癸二酮 、 borane 、 四氢呋喃 以27%的产率得到
  参考文献：
  名称：

  SUEESS R., HELV. CHIM. ACTA , 1977, 60 NO 5, 1650-1656

  摘要：

  DOI：

文献信息

• COVALENT INHIBITORS OF KRAS G12C
  申请人：Araxes Pharma LLC

  公开号：US20160159738A1

  公开（公告）日：2016-06-09

  Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.

  提供了G12C突变K-Ras蛋白的不可逆抑制剂。还揭示了调节G12C突变K-Ras蛋白活性的方法以及治疗由G12C突变K-Ras蛋白介导的疾病的方法。
• COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS
  申请人：The General Hospital Corporation

  公开号：EP2911664A1

  公开（公告）日：2015-09-02
• [EN] COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS<br/>[FR] POLYTHÉRAPIES POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER ET DES TROUBLES ASSOCIÉS
  申请人：GEN HOSPITAL CORP

  公开号：WO2014066318A1

  公开（公告）日：2014-05-01

  The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.